Kazia Therapeutics Secures $2 Million to Fuel Cancer Research
Kazia Therapeutics Limited (NASDAQ: KZIA), a company dedicated to developing innovative oncology therapies, has recently entered into an agreement with institutional investors to raise $2 million through a private placement. The funding will further advance its clinical development programs, particularly focusing on therapies targeting brain cancer and breast cancer.
Details of the Private Placement
The private placement involves the sale of ordinary shares and prefunded warrants, priced at a 5% premium to the market closing price of Kazia's American Depositary Shares (ADSs) on a prior date. This structure allows for a direct equity investment without common warrant coverage. The transaction is anticipated to be finalized shortly, subject to standard closing conditions.
Utilization of Funds for Clinical Programs
The company plans to allocate the net proceeds from this offering primarily to bolster the ongoing clinical trials of its lead product, paxalisib, a dual PI3K/mTOR inhibitor that aims to treat aggressive brain cancers, including glioblastoma and other advanced solid tumors. Additionally, part of the funding will support EVT801, a selective VEGFR3 inhibitor currently undergoing trials for advanced solid tumors.
CEO Statement on the Transaction
Dr. John Friend, CEO of Kazia Therapeutics, expressed optimism regarding the funding, stating, "This transaction provides Kazia with additional capital to advance our clinical-stage assets through key near-term catalysts most notably additional data from our ongoing advanced breast cancer trial. We are grateful for the continued support of our investors and look forward to delivering updates on upcoming milestones." His remarks encapsulate the company’s vision of utilizing the funding to expedite research and development efforts.
Company Overview and Research Initiatives
Kazia Therapeutics is focused on creating revolutionary cancer treatments. Their portfolio includes not only paxalisib but also investigational therapies like EVT801, which aim to combat cancer by targeting key biological pathways involved in tumor growth. The commitment to innovation is evident as Kazia works diligently to transition these assets through clinical development and into commercial use, addressing unmet medical needs in oncology.
Contact Information for Inquiries
For more information, investor relations, or media inquiries, contact Alex Star, Managing Director at LifeSci Advisors LLC. He can be reached via email at Astarr@lifesciadvisors.com or by phone at +1-201-786-8795.
Frequently Asked Questions
What is the purpose of the $2 million raised by Kazia Therapeutics?
The funds will support clinical programs for their lead products, including paxalisib and EVT801.
Who is the CEO of Kazia Therapeutics?
Dr. John Friend is the CEO of Kazia Therapeutics, emphasizing the importance of this funding for the company's future.
Where is Kazia Therapeutics based?
Kazia Therapeutics is based in Australia and focuses on developing innovative treatments for cancer.
What are the main cancer treatments Kazia is focusing on?
Kazia is particularly focused on paxalisib for brain cancer and EVT801 for various advanced solid tumors.
How has the market reacted to Kazia's recent funding announcement?
While specific market reactions vary, investors generally view funding announcements as positive indicators of a company's growth potential.
